Feb
22
EMEA CMPH Use Adopts 5 Positive Opinions Recommending The Granting Of A Marketing Authorisation For The Following Medicinal Products
February 22, 2010 | | Leave a Comment
– Aerinaze (desloratadine 2.5 mg/pseudoephedrine sulphate 120 mg), from Schering-Bulldoze Europe, for the symptomatic treatment of seasonal allergic rhinitis, accompanied by nasal congestion. EMEA cavalcade began on 26 July 2006 with an active re-examination time of 196 days.
– Increlex (mecasermin), from Tercica Europe Ltd, for the long-span of time treatment of growth folding in children and adolescents with severe pinnacle insulin-a charge out of prefer growth factor1 deficiency or with growth hormone (GH) gene deletion who have developed neutralising antibodies to GH. Increlex is the 39th orphan restorative product to hear a positive impression. The CHMP recommended the granting of a marketing authorisation under exceptional circumstances. Such authorisations are admissible inasmuch as sanative products for the duration of which the applicant can demonstrate that comprehensive data cannot be provided, for example because of the rarity of the demand, as long as it can be demonstrated on a regular infrastructure that the benefits make up for the risks. EMEA review began on 28 December 2005 with an active review continually of 208 days.
– Mircera (methoxy polyethylene glycol-epoetin beta), from Roche Registration Ltd, for the benefit of the treatment of anaemia associated with chronic kidney disease. EMEA flyover began on 24 May 2006 with an active over again occasion of 176 days.
– Optimark (gadoversetamide), from Tyco Healthcare Deutschland GmbH, into turn to account in captivating resonance imaging. EMEA review began on 24 May 2006 with an active review time of 196 days.
– Orlistat GSK (orlistat), from Glaxo Group Ltd trading as GlaxoSmithKline, for the treatment of the treatment of obese patients and overweight patients with associated endanger factors. The application someone is concerned marketing authorisation fitted Orlistat GSK was made as an ‘informed consent’ application to Xenical, from Roche Registration Ltd. This type of relevance requires that regard be made to an authorised medicinal product and that the marketing authorisation holder of this allusion product confer permission to the use of the dossier in the application procedure. EMEA weigh began on 25 March 2007 with an active consider time of 60 days.
Negative opinions
The CHMP adopted a nullifying theory recommending the refusal of a marketing authorisation to save Vectibix (panitumumab), from Amgen Europe B.V., intended for the treatment of metastatic carcinoma of the colon or rectum after failure of oxaliplatin- and/or irinotecan- containing chemotherapy regimens.
A separate question-and-replication document explaining the grounds looking for the negative appraisal for Vectibix
Comments
You must be logged in to post a comment.
learnedwork